Brolucizumab
Brolucizumab Basic information
- Product Name:
- Brolucizumab
- Synonyms:
-
- Brolucizumab
- Research Grade Brolucizumab (DHD12603)
- Research Grade Brolucizumab
- CAS:
- 1531589-13-5
- MW:
- 0
- Mol File:
- Mol File
Brolucizumab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Brolucizumab Usage And Synthesis
Uses
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer[1][2].
in vivo
Brolucizumab (15 mg/kg; i.p. 5 days per week for 21 or 41 days) slows the growth of mSLK-KSHV xenograft tumors[2].
Brolucizumab (5-50 mg/kg; i.p. once or twice daily for 28 days) delays in vivo tumor growth in U87MG glioma models[1].
Brolucizumab (10 mg/kg; i.v.) shows a half-life of 5.4-7.8 minutes for the rapid decline phase and 1.4-1.9 hours for the slow decline phase in mice[2].
| Animal Model: | NSG mice were subcutaneously injected with mSLK-KSHV cell suspension[2] |
| Dosage: | 15 mg/kg |
| Administration: | I.p. 5 days per week for 21 or 41 days |
| Result: | Significantly lowed tumor growth there was no difference in survival between experimental and combined control groups. |
References
[1] Szabó E, et, al. Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther. 2018 May;365(2):422-429. DOI:10.1124/jpet.117.246249
[2] Eason AB, et, al. DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS One. 2020 May 14;15(5):e0233116. DOI:10.1371/journal.pone.0233116
BrolucizumabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com